Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 21 unusual trades.
Delving into the details, we found 28% of traders were bullish, while 52% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $168,350, and 17 were calls, valued at $1,103,918.
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $400.0 to $1080.0 for Eli Lilly over the recent three months.
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale activity within a strike price range from $400.0 to $1080.0 in the last 30 days.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | CALL | SWEEP | BEARISH | 12/19/25 | $143.95 | $137.65 | $139.35 | $940.00 | $249.1K | 220 | 17 |
LLY | CALL | TRADE | NEUTRAL | 01/16/26 | $410.4 | $399.8 | $405.8 | $550.00 | $202.9K | 57 | 0 |
LLY | CALL | SWEEP | BULLISH | 09/13/24 | $5.0 | $4.65 | $5.0 | $930.00 | $92.5K | 906 | 252 |
LLY | CALL | TRADE | BULLISH | 11/15/24 | $61.0 | $59.05 | $61.0 | $910.00 | $54.9K | 230 | 15 |
LLY | PUT | TRADE | NEUTRAL | 09/13/24 | $58.4 | $52.0 | $54.85 | $960.00 | $54.8K | 47 | 0 |
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1019.2.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, Benzinga Pro gives you real-time options trades alerts.
Posted In: LLY